SciSure is a platform for managing laboratory operations end-to-end, built for scientific organizations. It brings together ELN, LIMS, and Health & Safety tools so teams can document experiments, track samples, manage chemical inventory, and maintain compliance workflows that are structured and audit-ready.
By replacing fragmented systems with a single governed platform, SciSure helps organizations improve reproducibility, gain clearer operational visibility, and scale lab operations with less risk.
Learn more
Revaly is built to solve one of the most costly and overlooked problems in subscription commerce: legitimate payments failing for preventable reasons. Its end-to-end Payment Performance Management platform leverages machine learning, issuer intelligence, and ecosystem data to elevate approval rates starting from the very first transaction attempt. The system automatically detects issues such as mistyped card numbers, routing mismatches, and metadata errors before a customer ever checks out. When payments do fail, Revaly uses a sophisticated retry engine that studies customer behavior, card network patterns, and historical success windows to recover revenue without damaging relationships. Businesses across industries report dramatic improvements—from 34% to over 50% increases in recovered payments—demonstrating the compound value of consistent, optimized approvals. Revaly’s integration ecosystem makes adoption frictionless, connecting seamlessly with CRMs, billing systems, payment gateways, and processors already in use. The platform not only protects revenue but stabilizes growth by reducing churn that comes from unintentional payment failures. Leadership teams gain visibility into payment performance metrics that go far beyond authorization rates, revealing hidden revenue opportunities and operational inefficiencies. As a result, companies can build smarter billing strategies and deliver a more reliable experience for customers. Revaly becomes a trusted partner in improving profitability, ensuring that when a customer says “yes,” the payment system does too.
Learn more
Iktos
Makya emerges as a groundbreaking user-focused SaaS platform specifically tailored for AI-driven de novo drug design, with a particular focus on Multi-Parametric Optimization (MPO). This cutting-edge tool enables users to generate original and easily synthesizable compounds through a multi-objective framework, achieving unparalleled speed, efficiency, and diversity in results. Featuring a variety of generative algorithms that cater to different phases of drug development—from hit discovery to lead optimization—Makya includes a fine-tuning generator for identifying optimal solutions within your defined chemical space, a novelty generator aimed at uncovering new ideas for re-scaffolding and hit identification, and a forward generator that assembles a specialized library of compounds ready for synthesis using commercially accessible starting materials. The platform's latest addition, the Makya 3D module, markedly enhances both the user experience and scientific functionality. With an extensive toolkit of 3D modeling capabilities for both ligand-based and structure-based methodologies, Makya 3D facilitates the computation of 3D scores that can be effortlessly integrated to steer compound generation within the platform. This comprehensive integration not only refines the design workflow but also provides researchers with profound insights into their molecular architectures, ultimately transforming the drug discovery landscape. As researchers increasingly seek innovative solutions, Makya stands at the forefront, revolutionizing the way compounds are designed and developed.
Learn more
Schrödinger
Transform the domains of drug development and materials science by employing advanced molecular modeling approaches. Our computational platform, rooted in the principles of physics, offers distinct solutions for predictive modeling, data analysis, and collaborative efforts, enabling efficient exploration of chemical space. This state-of-the-art platform is utilized by top industries worldwide, supporting drug discovery projects and materials science endeavors in diverse fields such as aerospace, energy, semiconductors, and electronic displays. It propels our internal drug discovery initiatives, managing the entire process from identifying targets to discovering hits and optimizing leads. Moreover, it boosts our collaborative research aimed at developing innovative medicines to tackle major public health issues. With a dedicated team comprising over 150 Ph.D. scientists, we invest considerable resources into research and development. Our impact on the scientific community is highlighted by over 400 peer-reviewed publications that demonstrate the effectiveness of our physics-based approaches, ensuring we remain leaders in the evolution of computational modeling techniques. We are unwavering in our commitment to pioneering advancements and broadening the horizons of our industry while fostering partnerships that amplify our research capabilities.
Learn more
